RecruitingPHASE1, PHASE2NCT02174549
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Studying Embryonal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Teclison Ltd.
- Principal Investigator
- Michael Soulen, MDUniv. of Pennsylvania
- Intervention
- Tirapazamine(drug)
- Enrollment
- 25 target
- Eligibility
- 20-99 years · All sexes
- Timeline
- 2014 – 2028
Study locations (2)
- Stanford University, Palo Alto, California, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02174549 on ClinicalTrials.govOther trials for Embryonal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT04086485Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)National Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT05168631Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine TumorsLatin American Cooperative Oncology Group
- RECRUITINGNCT02688894The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]Samsung Medical Center
- RECRUITINGNANCT01980264Harmonics-based in Vivo Optical Virtual BiopsyNational Taiwan University Hospital